Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wai-Kay Seto

Showing results (151-160 of 326) with videos related to

Pageof 33
Sort By:
Gut|September 18, 2025
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort studyJing Tong Tan, Xianhua Mao, David Tak-Wai Lui, et al.
Hepatology International|January 24, 2019
Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infectionLung-Yi Mak, Danny Ka-Ho Wong, Wai-Kay Seto, et al.
Journal of Travel Medicine|May 5, 2021
Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changesYe Peng, Dengwei Zhang, Ting Chen, et al.
Idcases|June 27, 2018
Fatal pancytopenia due to albendazole treatment for strongyloidiasisFanfan Xing, Haiyan Ye, Jin Yang, et al.
Gut|August 9, 2024
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver diseaseXianhua Mao, Xinrong Zhang, Leslie Kam, et al.
Ebiomedicine|April 7, 2024
Virological response to nucleos(t)ide analogues treatment in chronic hepatitis B patients is associated with Bacteroides-dominant gut microbiomeSaisai Zhang, Hau-Tak Chau, Hein Min Tun, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 14, 2025
Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes MellitusHo Yu Ng, Lina Zhang, Jing Tong Tan, et al.
Journal of Hepatology|June 7, 2020
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis BLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Digestive Diseases and Sciences|March 8, 2022
Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus InfectionLung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNADanny Ka-Ho Wong, Wai-Kay Seto, Ka-Shing Cheung, et al.
Pageof 33

Showing results (151-160 of 326) with videos related to

Sort By:
Pageof 33
Gut|September 18, 2025
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort studyJing Tong Tan, Xianhua Mao, David Tak-Wai Lui, et al.
Hepatology International|January 24, 2019
Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infectionLung-Yi Mak, Danny Ka-Ho Wong, Wai-Kay Seto, et al.
Journal of Travel Medicine|May 5, 2021
Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changesYe Peng, Dengwei Zhang, Ting Chen, et al.
Idcases|June 27, 2018
Fatal pancytopenia due to albendazole treatment for strongyloidiasisFanfan Xing, Haiyan Ye, Jin Yang, et al.
Gut|August 9, 2024
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver diseaseXianhua Mao, Xinrong Zhang, Leslie Kam, et al.
Ebiomedicine|April 7, 2024
Virological response to nucleos(t)ide analogues treatment in chronic hepatitis B patients is associated with Bacteroides-dominant gut microbiomeSaisai Zhang, Hau-Tak Chau, Hein Min Tun, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 14, 2025
Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes MellitusHo Yu Ng, Lina Zhang, Jing Tong Tan, et al.
Journal of Hepatology|June 7, 2020
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis BLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Digestive Diseases and Sciences|March 8, 2022
Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus InfectionLung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNADanny Ka-Ho Wong, Wai-Kay Seto, Ka-Shing Cheung, et al.
Pageof 33